Treating Agitation: A New FDA Approval

How is this new drug going to help in the treatment of agitation in patients with schizophrenia or bipolar disorder?

John H. Krystal, MD, discusses the new FDA approval of BioXcel Therapeutics' dexmedetomidine (Igalmi™) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. To read more abou this approval, see "New Approval for Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder."

Dr Krystal is the Robert L. McNeil, Jr. professor of translational research; professor of psychiatry, neuroscience, and of psychology; and codirector at the Yale Center for Clinical Investigation. He also serves as chair and chief of psychiatry at Yale-New Haven Hospital. He is also the director of the NIAAA Center for the Translational Neuroscience of Alcoholism, and director of the clinical neuroscience division at the VA National Center for PTSD.